DM drugs

Question 1

sulfonylurea MOA

Answer 1

bind to sulfonylurea receptor on b-cells, stimulating insulin release

Question 2

glinides MOA (repaglinide, nateglinide)

Answer 2

Bind to sulfonylurea receptor on beta-cells, stimulating insulin release; short duration of action

Question 3

biguanides (metformin) MOA

Answer 3

decrease hepatic glucose production

Question 4

thiazolidinediones (pioglitazone, rosiglatizone) MOA

Answer 4

active PPARgame, increasing peripheral insulting sensitivity, may also reduce hepatic glucose production

Question 5

incretin modulators (eventide, liraglutide) MOA

Answer 5

Activate GLP-1 receptors, increasing glucose-dependent insulin secretion, decreasing glucagon secretion, delaying gastric emptying, and enhancing satiety

Question 6

DPP_4 inhibitors (sitagliptin, saxagliptin, vildagliptin) MOA

Answer 6

inhibit degradation of endogenous GLP-1 and Gip, thereby enhancing effect of these incretins on insulin and glucagon secretion

Question 7

alpha-glucosidase inhibitors (acarbose, miglitol, voglibose) MOA

Answer 7

inhibit polysaccharide absorption in the gut

Question 8

SGLT2 inhibitor (dapaglifozin, canglifozin) MOA

Answer 8

inhibit SGLT2 in proximal renal tubules to reduce renal reabsorption of filtered glucose resulting glucosuria